235 related articles for article (PubMed ID: 11773186)
1. STI571: a paradigm of new agents for cancer therapeutics.
Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
[TBL] [Abstract][Full Text] [Related]
2. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the development of a molecularly targeted agent.
Druker BJ
Cancer Cell; 2002 Feb; 1(1):31-6. PubMed ID: 12086885
[TBL] [Abstract][Full Text] [Related]
4. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
O'Dwyer ME; Druker BJ
Curr Cancer Drug Targets; 2001 May; 1(1):49-57. PubMed ID: 12188891
[TBL] [Abstract][Full Text] [Related]
5. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
O'Dwyer ME; Druker BJ
Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
[TBL] [Abstract][Full Text] [Related]
6. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
7. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
9. STI571 (imatinib mesylate): the tale of a targeted therapy.
Thambi P; Sausville EA
Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
[TBL] [Abstract][Full Text] [Related]
10. STI571 as a targeted therapy for CML.
O'Dwyer ME; Mauro MJ; Druker BJ
Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
[TBL] [Abstract][Full Text] [Related]
11. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
12. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
[TBL] [Abstract][Full Text] [Related]
13. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
14. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
15. Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Sausville EA
J Natl Cancer Inst; 2000 Oct; 92(20):1626-7. PubMed ID: 11036101
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
17. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
18. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
[TBL] [Abstract][Full Text] [Related]
19. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
20. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Hofmann WK; Jones LC; Lemp NA; de Vos S; Gschaidmeier H; Hoelzer D; Ottmann OG; Koeffler HP
Blood; 2002 Mar; 99(5):1860-2. PubMed ID: 11861307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
